BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/360/0.1/20.12.24

BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/360/0.1/20.12.24 Stock

DE000VD3R7P5

Market Closed - Boerse Frankfurt Warrants 13:52:26 2024-06-27 EDT
0.35 ^EUR	-10.26%

Current month	-57.32%
1 month	-40.68%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/360/0.1/20.12.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	06-27	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	06-24	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	06-21	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-27	0.35	-10.26%
24-06-26	0.39	0.00%
24-06-25	0.39	0.00%
24-06-24	0.39	-15.22%
24-06-21	0.46	+9.52%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 01:52 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Vontobel
WKN	VD3R7P
ISIN	DE000VD3R7P5
Date issued	2024-04-09
Strike	360 $
Maturity	2024-12-20 (176 Days)
Parity	10 : 1
Emission price	1.43 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	2.07 €
Lowest since issue	0.29 €
Spread	0.04 €
Spread %	9.09%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company